Zura Bio Shares Plunge After Phase 2 Hidradenitis Suppurativa Trial Misses Endpoints
Zura Bio shares plunged after its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet primary and key secondary endpoints.
Zura Bio shares plunged after its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet primary and key secondary endpoints.
The acquisition adds Frontage’s clinical bioanalysis expertise and strengthens Charles River’s drug development offering.
Early data show 70% two-year survival with brenetafusp plus KIMMTRAK in first-line metastatic uveal melanoma. Median OS not reached after 29 months.
Lilly partners with Hims & Hers so patients can access Zepbound ($299/mo) and Foundayo ($149/mo) at self-pay prices on the telehealth platform.
ANIP announced a public offer to acquire Egetis Therapeutics, bringing in EMCITATE, the first approved treatment for MCT8 deficiency.
William Blair says updated ASH abstract data for Cullinan’s CLN-049 show lower response rates, sending shares down. Analyst keeps Outperform.